Cargando…

Vaccinia Virus Strain MVA Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Glycoprotein Induces Robust Protection and Prevents Brain Infection in Mouse and Hamster Models

The COVID-19 pandemic has underscored the importance of swift responses and the necessity of dependable technologies for vaccine development. Our team previously developed a fast cloning system for the modified vaccinia virus Ankara (MVA) vaccine platform. In this study, we reported on the construct...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lorenzo, María M., Marín-López, Alejandro, Chiem, Kevin, Jimenez-Cabello, Luis, Ullah, Irfan, Utrilla-Trigo, Sergio, Calvo-Pinilla, Eva, Lorenzo, Gema, Moreno, Sandra, Ye, Chengjin, Park, Jun-Gyu, Matía, Alejandro, Brun, Alejandro, Sánchez-Puig, Juana M., Nogales, Aitor, Mothes, Walther, Uchil, Pradeep D., Kumar, Priti, Ortego, Javier, Fikrig, Erol, Martinez-Sobrido, Luis, Blasco, Rafael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220993/ https://www.ncbi.nlm.nih.gov/pubmed/37243110 http://dx.doi.org/10.3390/vaccines11051006

Ejemplares similares

Modeling Arboviral Infection in Mice Lacking the Interferon Alpha/Beta Receptor
por: Marín-Lopez, Alejandro, et al.
Publicado: (2019)

Heterologous Combination of ChAdOx1 and MVA Vectors Expressing Protein NS1 as Vaccination Strategy to Induce Durable and Cross-Protective CD8+ T Cell Immunity to Bluetongue Virus
por: Utrilla-Trigo, Sergio, et al.
Publicado: (2020)

The Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS2(1-180)) by ChAdOx1 and MVA Confers Protection against Clinical Disease in Sheep upon Bluetongue Virus Challenge
por: Utrilla-Trigo, Sergio, et al.
Publicado: (2022)

Vaccinia Virus Attenuation by Codon Deoptimization of the A24R Gene for Vaccine Development
por: Lorenzo, María M., et al.
Publicado: (2022)

Viral Vector Vaccines against Bluetongue Virus
por: Jiménez-Cabello, Luis, et al.
Publicado: (2020)

A protective bivalent vaccine against Rift Valley fever and bluetongue
por: Calvo-Pinilla, Eva, et al.
Publicado: (2020)

Inhibition of Orbivirus Replication by Aurintricarboxylic Acid
por: Alonso, Celia, et al.
Publicado: (2020)

Reverse genetics approaches: a novel strategy for African horse sickness virus vaccine design
por: Calvo-Pinilla, Eva, et al.
Publicado: (2020)

Natural Selection of H5N1 Avian Influenza A Viruses with Increased PA-X and NS1 Shutoff Activity
por: Nogales, Aitor, et al.
Publicado: (2021)

Bi-Reporter Vaccinia Virus for Tracking Viral Infections In Vitro and In Vivo
por: Chiem, Kevin, et al.
Publicado: (2021)

Epizootic Hemorrhagic Disease Virus: Current Knowledge and Emerging Perspectives
por: Jiménez-Cabello, Luis, et al.
Publicado: (2023)

Increasing the Safety Profile of the Master Donor Live Attenuated Influenza Vaccine
por: Hilimire, Thomas A., et al.
Publicado: (2020)

Amino Acid Residues Involved in Inhibition of Host Gene Expression by Influenza A/Brevig Mission/1/1918 PA-X
por: Chiem, Kevin, et al.
Publicado: (2021)

Mosquito Salivary Proteins and Arbovirus Infection: From Viral Enhancers to Potential Targets for Vaccines
por: Marín-López, Alejandro, et al.
Publicado: (2023)

Efficacy of different DNA and MVA prime-boost vaccination regimens against a Rift Valley fever virus (RVFV) challenge in sheep 12 weeks following vaccination
por: Lorenzo, Gema, et al.
Publicado: (2018)

Nanoparticle- and Microparticle-Based Vaccines against Orbiviruses of Veterinary Importance
por: Jiménez-Cabello, Luis, et al.
Publicado: (2022)

MVA Vectored Vaccines Encoding Rift Valley Fever Virus Glycoproteins Protect Mice against Lethal Challenge in the Absence of Neutralizing Antibody Responses
por: López-Gil, Elena, et al.
Publicado: (2020)

The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host
por: Calvo-Pinilla, Eva, et al.
Publicado: (2018)

Reverse Genetics Approaches for the Development of Influenza Vaccines
por: Nogales, Aitor, et al.
Publicado: (2016)

A Modified Vaccinia Ankara Virus (MVA) Vaccine Expressing African Horse Sickness Virus (AHSV) VP2 Protects Against AHSV Challenge in an IFNAR −/− Mouse Model
por: Castillo-Olivares, Javier, et al.
Publicado: (2011)

Identification of In Vitro Inhibitors of Monkeypox Replication
por: Chiem, Kevin, et al.
Publicado: (2023)

A New Master Donor Virus for the Development of Live-Attenuated Influenza B Virus Vaccines
por: White, Chantelle L., et al.
Publicado: (2021)

Temperature Sensitive Mutations in Influenza A Viral Ribonucleoprotein Complex Responsible for the Attenuation of the Live Attenuated Influenza Vaccine
por: Martínez-Sobrido, Luis, et al.
Publicado: (2018)

Identification of β2 microglobulin, the product of B2M gene, as a Host Factor for Vaccinia Virus Infection by Genome-Wide CRISPR genetic screens
por: Matía, Alejandro, et al.
Publicado: (2022)

Protection of IFNAR (−/−) Mice against Bluetongue Virus Serotype 8, by Heterologous (DNA/rMVA) and Homologous (rMVA/rMVA) Vaccination, Expressing Outer-Capsid Protein VP2
por: Jabbar, Tamara Kusay, et al.
Publicado: (2013)

CD8 T Cell Responses to an Immunodominant Epitope within the Nonstructural Protein NS1 Provide Wide Immunoprotection against Bluetongue Virus in IFNAR(−/−) Mice
por: Marín-López, Alejandro, et al.
Publicado: (2018)

Live attenuated influenza A virus vaccines with modified NS1 proteins for veterinary use
por: Nogales, Aitor, et al.
Publicado: (2022)

Can vaccinia virus be replaced by MVA virus for testing virucidal activity of chemical disinfectants?
por: Rabenau, Holger F, et al.
Publicado: (2010)

Replication-Competent Influenza A Viruses Expressing Reporter Genes
por: Breen, Michael, et al.
Publicado: (2016)

Novel Approaches for The Development of Live Attenuated Influenza Vaccines
por: Blanco-Lobo, Pilar, et al.
Publicado: (2019)

A Broad and Potent H1-Specific Human Monoclonal Antibody Produced in Plants Prevents Influenza Virus Infection and Transmission in Guinea Pigs
por: Park, Jun-Gyu, et al.
Publicado: (2020)

Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects
por: Frey, Sharon E., et al.
Publicado: (2015)

Functional Characterization and Direct Comparison of Influenza A, B, C, and D NS1 Proteins in vitro and in vivo
por: Nogales, Aitor, et al.
Publicado: (2019)

Selection, identification, and characterization of SARS-CoV-2 monoclonal antibody resistant mutants
por: Oladunni, Fatai S., et al.
Publicado: (2021)

A Genotype of Modified Vaccinia Ankara (MVA) that Facilitates Replication in Suspension Cultures in Chemically Defined Medium
por: Jordan, Ingo, et al.
Publicado: (2013)

Environmental Risk Assessment of Clinical Trials Involving Modified Vaccinia Virus Ankara (MVA)-Based Vectors
por: Goossens, Martine, et al.
Publicado: (2013)

Strikingly poor CD8(+) T cell immunogenicity of vaccinia virus strain MVA in BALB/c mice
por: Russell, Tiffany A., et al.
Publicado: (2014)

Genome Sequencing of a Camelpox Vaccine Reveals Close Similarity to Modified Vaccinia virus Ankara (MVA)
por: Marcacci, Maurilia, et al.
Publicado: (2020)

Diversity of cell death signaling pathways in macrophages upon infection with modified vaccinia virus Ankara (MVA)
por: Klaas, Lioba, et al.
Publicado: (2021)

HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine
por: Shen, Xiaoying, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_dth1d6rvmmc0gtd1vc2h4vgj42